# OnCo record prostate (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate" ;
  schema:name "Prostate cancer"@en ;
  schema:description "Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."@en ;
  schema:url <https://onco.cc/cancers/prostate/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q181257> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer> ;
  onco:tag "gu", "spike" ;
  onco:related <https://onco.cc/roadmaps/radiopharma-roadmap/>, <https://onco.cc/pairings/psma-pet-to-rlt/>, <https://onco.cc/pairings/beta-then-alpha/>, <https://onco.cc/pairings/parp-plus-arpi/>, <https://onco.cc/pairings/ai-pathology-to-adt/>, <https://onco.cc/collections/src-urotoday/> ;
  onco:technologies <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/psma/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/steap1/>, <https://onco.cc/targets/klk2/>, <https://onco.cc/targets/grpr/>, <https://onco.cc/targets/ezh2/> ;
  onco:drugs <https://onco.cc/drugs/paige-prostate/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/nilutamide/>, <https://onco.cc/drugs/triptorelin/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/padeliporfin/>, <https://onco.cc/drugs/samarium-153-lexidronam/> ;
  onco:companies <https://onco.cc/companies/halda-therapeutics/>, <https://onco.cc/companies/orion-orion-pharma/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/futurechem/>, <https://onco.cc/companies/hinova-pharmaceuticals/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/spectracure/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/lantheus/>, <https://onco.cc/companies/telix/>, <https://onco.cc/companies/curium/>, <https://onco.cc/companies/veracyte/>, <https://onco.cc/companies/artera/> ;
  onco:institutions <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/icr-london/>, <https://onco.cc/institutions/peter-mac/>, <https://onco.cc/institutions/ucla-jonsson/>, <https://onco.cc/institutions/uke-hamburg/>, <https://onco.cc/institutions/johns-hopkins/>, <https://onco.cc/institutions/gustave-roussy/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/prostate-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/psa/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/biochemical-recurrence/>, <https://onco.cc/terms/psa50/>, <https://onco.cc/terms/ar-v7/>, <https://onco.cc/terms/theranostics/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/crossover/> ;
  onco:trials <https://onco.cc/trials/nct06136624/>, <https://onco.cc/trials/nct06136650/>, <https://onco.cc/trials/nct06952803/>, <https://onco.cc/trials/nct06120491/>, <https://onco.cc/trials/nct06855277/>, <https://onco.cc/trials/nct06780670/>, <https://onco.cc/trials/nct07365995/>, <https://onco.cc/trials/nct06764485/>, <https://onco.cc/trials/mcrpc/>, <https://onco.cc/trials/himalayas-1/>, <https://onco.cc/trials/nct07311694/>, <https://onco.cc/trials/nct07615101/>, <https://onco.cc/trials/nct07649122/>, <https://onco.cc/trials/nct05381103/>, <https://onco.cc/trials/rtog-9601/>, <https://onco.cc/trials/horrad/>, <https://onco.cc/trials/pop-rt/>, <https://onco.cc/trials/nct06629779/>, <https://onco.cc/trials/nct05348577/>, <https://onco.cc/trials/nct05939414/>, <https://onco.cc/trials/nct06520345/>, <https://onco.cc/trials/nct07028853/>, <https://onco.cc/trials/nct01436968/>, <https://onco.cc/trials/nct03706365/>, <https://onco.cc/trials/nct04076059/>, <https://onco.cc/trials/nct05884398/>, <https://onco.cc/trials/nct07213674/>, <https://onco.cc/trials/nct04446117/>, <https://onco.cc/trials/nct06925737/>, <https://onco.cc/trials/nct07052214/>, <https://onco.cc/trials/nct05171816/>, <https://onco.cc/trials/nct07611110/>, <https://onco.cc/trials/nct04691804/>, <https://onco.cc/trials/nct05794906/>, <https://onco.cc/trials/nct02489318/>, <https://onco.cc/trials/nct04557059/>, <https://onco.cc/trials/nct03348670/>, <https://onco.cc/trials/nct06235151/>, <https://onco.cc/trials/nct02257736/>, <https://onco.cc/trials/nct06754085/>, <https://onco.cc/trials/nct06970847/>, <https://onco.cc/trials/nct04821622/>, <https://onco.cc/trials/nct05288166/>, <https://onco.cc/trials/nct07225946/>, <https://onco.cc/trials/nct04497844/>, <https://onco.cc/trials/nct03767244/>, <https://onco.cc/trials/nct02531516/>, <https://onco.cc/trials/nct01946204/>, <https://onco.cc/trials/nct06056830/>, <https://onco.cc/trials/nct03851640/> ;
  onco:people <https://onco.cc/people/chris-hoy/> ;
  onco:journals <https://onco.cc/journals/clinical-genitourinary-cancer/>, <https://onco.cc/journals/prostate-cancer-and-prostatic-diseases/>, <https://onco.cc/journals/urologic-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/cetrelimab/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/qlc5508/>, <https://onco.cc/drugs/opevesostat/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/aglatimagene-besadenovec/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/aaa817/>, <https://onco.cc/drugs/pf-07248144/>, <https://onco.cc/drugs/bnt324/>, <https://onco.cc/drugs/bms-986365/>, <https://onco.cc/drugs/jnj-87189401/>, <https://onco.cc/drugs/rinzimetostat/>, <https://onco.cc/drugs/hrs-4357/>, <https://onco.cc/drugs/fpi-2265/>, <https://onco.cc/drugs/xnw5004/>, <https://onco.cc/drugs/azd6621/>, <https://onco.cc/drugs/azd9750/>, <https://onco.cc/drugs/qlh12016/>, <https://onco.cc/drugs/amo959/>, <https://onco.cc/drugs/rv001v/>, <https://onco.cc/drugs/vudalimab/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/drugs/nuv-1511/>, <https://onco.cc/trials/alphabreak/>, <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/trials/xalute/>, <https://onco.cc/drugs/pasritamig/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/trials/mevpro-1/>, <https://onco.cc/drugs/lu177-psma-it/>, <https://onco.cc/trials/eclipse-psma/>, <https://onco.cc/ideas/idea-psma-pet-guided-mdt/>, <https://onco.cc/ideas/idea-alpha-first-mhspc/>, <https://onco.cc/targets/grpr/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/decipher-prostate/> ;
  onco:standardOfCare <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/trials/vision/>, <https://onco.cc/trials/psmafore/>, <https://onco.cc/terms/psa/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/trials/precision-mri/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/trials/protect/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/terms/biochemical-recurrence/>, <https://onco.cc/trials/embark/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/ideas/idea-psma-pet-guided-mdt/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/drugs/darolutamide/>, <https://onco.cc/drugs/relugolix/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/trials/arasens/>, <https://onco.cc/trials/peace-1/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/trials/psmaddition/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/trials/capitello-281/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/darolutamide/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/propel/>, <https://onco.cc/trials/talapro-2/>, <https://onco.cc/trials/magnitude/>, <https://onco.cc/trials/profound/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/trials/psmafore/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/trials/vision/>, <https://onco.cc/drugs/cabazitaxel/>, <https://onco.cc/drugs/radium-223/>, <https://onco.cc/trials/alsympca/>, <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/trials/alphabreak/>, <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/trials/xalute/>, <https://onco.cc/drugs/pasritamig/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/trials/mevpro-1/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/> .